ProSomnus, Inc. Stock Price, News & Analysis

ProSomnus, Inc. (NASDAQ: OSA), a leader in precision medical devices for treating Obstructive Sleep Apnea (OSA), will release its Q1 financial results after market close on May 9, 2023. CEO Len Liptak and CFO Brian Dow will discuss the results during a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can register for the call via the provided link.

Additionally, ProSomnus will participate in two upcoming investor conferences: the EF Hutton Global Conference on May 10, 2023 and the 20th Annual Craig-Hallum Institutional Investor Conference on May 31, 2023. ProSomnus’s precision intraoral devices provide effective treatment for OSA, impacting over 74 million people in North America, and are gaining recognition for their patient-preferred outcomes.

ProSomnus, a leader in precision medical devices for Obstructive Sleep Apnea (OSA), announced findings from a recent study highlighting the effectiveness of its Precision Oral Appliance Therapy (OAT) compared to traditional methods. Presented at the 2023 Sleep and Breathing Conference, the study reveals that Precision OAT demonstrated a 100% efficacy rate in mild OSA cases, outperforming traditional OAT's 85%. For mild to moderate OSA, the median efficacy stood at 92% for Precision OAT versus 75% for traditional OAT. Even in severe cases, Precision OAT led with 59% efficacy compared to 50% for traditional options. ProSomnus continues to lead the market, with over 200,000 devices delivered, offering an effective alternative to CPAP therapy.

ProSomnus, Inc. (NASDAQ: OSA) has announced the publication of four abstracts in the Journal of Dental Sleep Medicine, which will be presented at the 2023 AADSM Annual Meeting in Philadelphia from May 19-21. The abstracts cover significant studies, including a comparison of efficacy between precision oral appliance therapy and traditional methods, and an analysis of adverse events related to various sleep apnea treatments.

The studies highlight ProSomnus’s position as a leader in precision medical devices for Obstructive Sleep Apnea (OSA), a condition affecting over 74 million people in North America. The company's FDA-cleared devices are recognized for being less invasive and more comfortable than CPAP therapy, making them a patient-preferred option.

ProSomnus, Inc. (NASDAQ: OSA) announced that the U.S. Patent and Trademark Office granted U.S. patent serial number 11,617,677 on April 4, 2023. This patent adds to ProSomnus's impressive portfolio, now totaling 17 issued patents covering its iterative titration technology for Precision Oral Appliance Therapy (OAT) devices. This technology enhances device performance by improving airflow and patient comfort. ProSomnus's FDA-cleared devices offer a competitive alternative to traditional CPAP machines, demonstrating strong patient compliance and efficacy. Over 200,000 devices have been delivered, underlining their demand in the OSA treatment market.

ProSomnus, Inc. (NASDAQ: OSA) reported financial results for Q4 and FY 2022, with revenues of $5.8 million for Q4 and $19.4 million for the year, marking increases of 32% and 38% respectively from 2021. The company surpassed 200,000 devices prescribed and expanded growth initiatives, including increasing its sales team and launching new products. Gross margin improved to 53.6% in Q4 while sales and marketing expenses surged by over 44%. Research and development costs rose significantly due to new product development and clinical studies. General and administrative expenses included costs from the recent business combination.

ProSomnus, Inc. (NASDAQ: OSA) announced that the U.S. Patent and Trademark Office has allowed a patent for its automated manufacturing process. This brings the total to 16 issued patents, enhancing its intellectual property related to precision medical devices for Obstructive Sleep Apnea (OSA). ProSomnus's Precision OAT devices are FDA-cleared and offer an effective alternative to traditional treatments like CPAP. The company emphasizes its innovative manufacturing processes to meet growing demand while maintaining device effectiveness and patient comfort. ProSomnus has delivered over 200,000 devices, making it the most prescribed Precision OAT in the U.S.

ProSomnus, Inc. (NASDAQ: OSA) announced it will release its fourth-quarter and full-year 2022 financial results on March 30, 2023, after market close. CEO Len Liptak and CFO Brian Dow will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide a business update.

ProSomnus specializes in precision medical devices for Obstructive Sleep Apnea (OSA). Their patented devices offer a less invasive alternative to CPAP therapy and are the most prescribed Precision Oral Appliance Therapy in the U.S., with over 200,000 devices delivered.

ProSomnus, Inc. (NASDAQ: OSA), a leader in precision medical devices for Obstructive Sleep Apnea (OSA), announced a significant development with an abstract on the efficacy of its Precision Oral Appliance Therapy (OAT) being accepted for presentation at the Sleep and Breathing 2023 Conference in Prague, scheduled for April 20-22, 2023.

Dr. Shouresh Charkhandeh will present the findings on April 20. ProSomnus’s FDA-cleared devices offer patient-specific solutions, demonstrating excellent efficacy and compliance compared to traditional treatments, including CPAP machines.

With over 200,000 devices delivered, ProSomnus’s products are widely prescribed, supported by positive clinical research outcomes, and are recognized by key health programs.